Benzinga | Dec 21, 2021 08:31AM EST

Rigel Announces Fostamatinib Met Primary Endpoint In Phase 3 Trial In Japan For Treatment Of Chronic Immune Thrombocytopenia

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), today announced that its collaboration partner, Kissei Pharmaceutical Co., Ltd. ("Kissei"), has released positive topline results from its Phase 3 clinical trial in Japan evaluating fostamatinib disodium hexahydrate for the treatment of adult chronic immune thrombocytopenia (ITP).